Table 1 Parameters used in the dynamic transmission model
From: Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England
Parameter | Value and uncertainty | Source |
|---|---|---|
Efficacy against B strain(s) | ||
TIIV and LAIV, < 65 years | 42% | [3] |
TIIV and LAIV, 65+ years | 28% | [3] |
QIIV and QLAIV, < 65 years § | 70% (min. 50%, max. 90%) | [3] |
QIIV and QLAIV, 65+ years § | 46% (min. 30%, max. 70%) | [3] |
Influenza vaccination coverage | ||
Low-risk < 5 years § | 33.7% (±10%) | [17] |
Low-risk 5–16 years § | 54.9% (±10%) | [17] |
Clinical risk < 6 months–64 years § | 45.1% (±10%) | [17] |
65+ years § | 71.0% (±10%) | [17] |
Health care resource costs | ||
GP consultation | £46, lognormal (mean 46, standard deviation 8.4) | [3] |
Inpatient admission | £1050, lognormal (mean 1050, standard deviation 192.1) | [3] |